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OBJECTIVE — Growth deferentiation factor-15 (GDF-15) is involved in inﬂammation and
apoptosis. Expression is induced in the heart in response to ischemia and in atherosclerotic
plaques.TheaimofthisstudywastoinvestigateGDF-15levelsinrelationtoall-causemortality,
cardiovascularmortalityandmorbidity,declineinglomerularﬁltrationrate(GFR),andprogres-
sion toward end-stage renal disease (ESRD).
RESEARCH DESIGN AND METHODS — The study was a prospective observational
follow-up study including 451 type 1 diabetic patients with diabetic nephropathy (274 men,
aged 42.1  0.5 years [means  SD], diabetes duration 28.3  8.9 years, GFR 76  33
ml/min/1.73 m
2) and a control group of 440 patients with longstanding type 1 diabetes and
persistent normoalbuminuria (232 men, aged 45.4  11.5 years, duration of diabetes 27.7 
10.1 years). The patients were followed for 8.1 (0.0–12.9) years (median [range]).
RESULTS — Among normoalbuminuric patients, GDF-15 above the median predicted an
adjusted (age, systolic blood pressure [sBP], and estimated GFR) increased risk of all-cause
mortality (hazard ratio [HR] 3.6 [95% CI 1.3–10.3]; P  0.014). Among patients with diabetic
nephropathy, higher (fourth quartile) versus lower (ﬁrst quartile) GDF-15 levels predict all-
cause mortality (covariate-adjusted [sex, age, smoking, blood pressure, A1C, cholesterol, GFR,
N-terminal prohormone B-type natriuretic peptide, antihypertensive treatment, and previous
cardiovascular events]; HR 4.86 [95% CI 1.37–17.30]) as well as fatal and nonfatal cardiovas-
cular events (adjusted HR 5.59 [1.23–25.43] and 3.55 [1.08–11.64], respectively). In addition,
higher GDF-15 levels predict faster decline in GFR (P  0.001) but not development of ESRD.
CONCLUSIONS — Higher levels of GDF-15 are a predictor of all-cause and cardiovascular
mortality and morbidity in patients with diabetic nephropathy. Furthermore, higher levels of
GDF-15 are associated with faster deterioration of kidney function.
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D
iabetes is associated with accelerated
atherosclerosis and an increased risk
of cardiovascular disease (CVD),
which has become the major cause of
morbidityandmortalityamongpatients
withdiabeticnephropathy(1).Leftven-
tricularhypertrophy,hypertension,and
diabetes are leading predictors for the
development of heart failure and sud-
den death (2,3). In general, the hyper-
trophic growth of the myocardium is
regulated by a number of pro- and an-
tigrowth factors, e.g., angiotensin-II
andB-typenatriureticpeptide(BNP)re-
lated to the transforming growth fac-
tor- superfamily (4–6).
Recently, growth differentiation
factor-15 (GDF-15) has been identiﬁed
as a novel anti-hypertrophic regulatory
factor (7). GDF-15 is generated as a 40-
kDa propeptide from which the NH2-
terminus is cleaved and a 30-kDa protein
secreted as the active form (8).
GDF-15 is induced in the hypertro-
phic and dilated cardiomyopathy fol-
lowing hypertension/volume overload,
ischemia, and heart failure, possibly via
proinﬂammatory cytokine and oxidative
stress-dependent signaling pathways
(9,10). GDF-15 is highly expressed in the
infarcted myocardium in predominantly
nondiabetic patients suffering an acute
myocardial infarction (MI) (9) and in ath-
erosclerotic plaques obtained from ca-
rotidarterysurgery(11).Inanestedcase-
control study, GDF-15 was shown to be
associated with adverse cardiovascular
outcomes in women (12). Furthermore,
GDF-15 has been shown to predict mor-
tality in patients with both ST-elevation
MI (STEMI) and non–STEMI, indepen-
dent of known biomarkers such as N-
terminal prohormone B-type natriuretic
peptide (NT-proBNP) (13,14).
Therefore,weinvestigatedthepredic-
tive value of circulating GDF-15 levels on
all-cause mortality, fatal and nonfatal
CVD, decline in GFR, as well as progres-
sion to end-stage renal disease (ESRD) in
a well-characterized population of type 1
diabetic patients with or without diabetic
nephropathy.
RESEARCH DESIGN AND
METHODS— From 1993 to 2000,
adult Caucasian patients with type 1 dia-
betesanddiabeticnephropathyattending
the outpatient clinic at the Steno Diabetes
Center were invited to participate in a
study of genetic risk factors for the devel-
opment of diabetic complications. Of
these patients, 73% accepted. Type 1 di-
abeteswasconsideredpresentiftheageat
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time to deﬁnite insulin therapy was 1
year. In total, 458 patients with diabetic
nephropathy deﬁned by persistent albu-
minuria (300 mg/24 h) in two out of
three consecutive measurements, the
presence of retinopathy, and the absence
of other kidney or urinary tract disease
were enrolled as case subjects.
The absence of diabetic nephropathy
(control subjects) was deﬁned as persis-
tent normoalbuminuria (30 mg/24 h)
after 15 years of type 1 diabetes in pa-
tients not treated with ACE inhibitors or
angiotensin-II receptor blockers. In total,
442 were included as control subjects.
Baseline clinical and laboratory
investigations
All patients had blood samples and phe-
notypic characteristics collected as part
of the European Rational Approach for
the Genetics of Diabetic Complications
(EURAGEDIC) project (15). Ofﬁce blood
pressure (BP) was measured twice using a
sphygmomanometer after at least 10 min
rest in the sitting position. The average
value of three readings at two min apart
was used for calculation.
From venous samples, A1C was mea-
sured by standard high-performance liquid
chromatography (normal range 4.1–6.4%)
(Tosoh automated glycohemoglobin ana-
lyzer; Tosoh Bioscience, Minato, Japan),
and cholesterol concentrations were deter-
mined by standard methods (Hitachi 912
system; Roche Diagnostics). Urinary albu-
min excretion rate was measured in 24-h
urine collections by an enzyme immunoas-
say.Serumcreatinineconcentrationwasde-
termined by a modiﬁed Jaffe method.
GFR was measured annually in pa-
tients with diabetic nephropathy after a
singleinjectionof3.7MBq
51Cr-EDTAby
determination of radioactivity in venous
blood samples taken 180, 200, 220, and
240 min after injection (16). The results
were standardized for 1.73 m
2 body sur-
faceareausingthepatient’ssurfaceareaat
the start of the study. The mean day-to-
day coefﬁcient of variation is 4% in our
laboratory. Linear regression analysis of
the GFR determinations in each individ-
ualwasusedtoestimatetherateofdecline
in kidney function.
In patients with normoalbuminuria,
GFR at baseline was estimated by the
four-variable Modiﬁcation of Diet in Re-
nal Disease (MDRD) equation (17). ESRD
was deﬁned as chronic dialysis or kidney
transplantation. Diabetic retinopathy
was assessed by fundus photography af-
ter pupillary dilatation and graded nil,
simplex, and proliferative retinopathy.
On the basis of standardized question-
naires, current smokers of one or more
cigarettes/cigars/pipes per day were
classiﬁed as smokers and all others as
nonsmokers. Major CVD events were
diagnosedasstroke,MI,coronaryartery
bypass graft, and/or percutanous coro-
nary intervention.
Measurements of GDF-15,
NT-proBNP, and CRP
Blood samples for determination of bio-
markers were collected in EDTA tubes
and centrifuged, and the plasma was
stored at 80°C until analysis. Plasma
GDF-15 was measured using a one-step
enzyme immunoassay based on the elec-
trochemiluminescence (ECLIA) technol-
ogy (Elecsys 2010). This method is very
comparable to the immunoradiometric
assay previously described in detail (18),
and the antibodies used for both assays
are identical [capture antibody: PAb 
GDF-15  goat IgG(IS); detection anti-
body: Mab  GDF-15  mouse-147627-
IgG (R&D Systems)].
TheNH2-terminalendofNT-proBNP
was determined by sandwich immunoas-
say (Elecsys 2010), also as previously de-
scribed (19). C-reactive protein (CRP)
was analyzed with a chemiluminescent
enzyme–labeled immunometric assay
(Hitachi). All measurements of GDF-15,
NT-proBNP, and CRP were performed by
Roche Diagnostics (Penzberg, Germany)
by investigators blinded to the character-
istics and outcomes of the patients.
Follow-up data
In a prospective observational study de-
sign, the patients were followed until an
endpointwasreached—tothelastvisitat
the Steno Diabetes Center or until 1 Sep-
tember 2006. The end points were all-
cause mortality, cardiovascular mortality,
major cardiovascular events, decline in
GFR, and development of ESRD.
All patients were traced through the
National Death Register and if a patient
diedbefore1September2006,thedateof
death was recorded and information on
the cause of death was obtained. Two ob-
servers reviewed all death certiﬁcates in-
dependently and the primary cause of
death was recorded. Additional available
information from necropsy reports was
included.Alldeathswereclassiﬁedascar-
diovascular deaths unless an unequivocal
noncardiovascular cause was established.
Information about CVD events and ESRD
was obtained from patient records or dis-
charge letters from other hospitals. In
total, plasma GDF-15 levels were deter-
mined and follow-up data were available
for451(98.5%)patientswithdiabeticne-
phropathy and 440 (99.5%) control sub-
jects. The study was performed in
accordancewiththeHelsinkiDeclaration,
with the local ethics committee’s ap-
proval, and all patients gave their in-
formed consent.
Statistical analysis
Normallydistributedvariablesaremeans
SD, whereas non-normally distributed
variables were log10 transformed before
analysis and are median (range). Com-
parisons between groups were per-
formed by unpaired Student t test,
ANOVA, or linear regression when ap-
propriate. The Chi
2 test was used to
compare noncontinuous variables. A
two-tailed P value of 0.05 was consid-
ered statistically signiﬁcant.
Multiple linear regression analysis
was used to determine the inﬂuence of
baseline level of GDF-15 on decline in
GFR.Alltime-to-endpointvariableswere
analyzed using a log-rank test and dis-
played in Kaplan–Meier plots. The rela-
tionsbetweenbaselineGDF-15levelsand
end points during follow-up were as-
sessed using Cox regression enter model
(all-cause mortality, fatal and nonfatal
CVD, and ESRD) by univariable and mul-
tivariable analyses displayed as unad-
justed and adjusted HRs, respectively.
HRs and 95% CIs for risk factors and sig-
niﬁcancelevelfor
2(likelihoodratiotest)
are given. Levels of NT-proBNP and
GDF-15 were normalized by log10 trans-
formation and thus the corresponding
HRs refers to a 10-fold rise in the vari-
ables.Inaddition,thepredictiveaccuracy
of GDF-15 were compared by generating
receiver operating characteristic (ROC)
curves for all-cause mortality and CVD
mortality, respectively, and the areas under
the curves (AUCs) were calculated for
patients with diabetic nephropathy. All
calculations were performed using a com-
mercially available program (version 14.0;
SPSS, Chicago, IL).
RESULTS
Baseline characteristics
The study population included two
groups: 451 patients with type 1 diabetes
and diabetic nephropathy and 440 con-
trol subjects with type 1 diabetes for 15
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Baselineclinicalandlaboratorycharacter-
istics of the 891 patients are shown in Ta-
ble 1. As expected, the patients with
diabetic nephropathy received more anti-
hypertensive medication and had higher
A1C, BP, S-creatinine, and total choles-
terol than patients with normoalbumin-
uria (P  0.05). In parallel, the plasma
GDF-15 concentration was higher in pa-
tients with diabetic nephropathy than in
normoalbuminuric patients (median
[range] 1,322 ng/l [443–17,735] vs. 749
ng/l [158–13,933], respectively; P 
0.001). On average, GFR was well pre-
served among the patients with diabetic
nephropathy(GFR7633[ml/min/1.73
m
2]).
Plasma concentration of GDF-15 did
not differ signiﬁcantly between type 1 di-
abetic men and women (P  0.99), but
correlated positively with age (r  0.06,
P0.001)andsBP(r0.15,P0.001)
and inversely related to increased esti-
mated GFR (eGFR) (r  0.42, P 
0.001).
Follow-up data
This study was a prospective observa-
tional follow-up study with a median fol-
low-up time until end point or last visit of
8.1 (0.0–12.9) years. Because of the low
number of events in the normoalbumin-
uric group, the analyses are restricted to
the median (749 ng/l) level of GDF-15
among these patients. During the fol-
low-up period, ﬁve patients (2%) with
GDF-15 levels below the median and 29
(13%) with GDF-15 levels above the me-
diandied.Thelog-ranktestdemonstrated
a signiﬁcant difference between the
groups(P0.001).Thiscorrespondedto
a sixfold increased risk for all-cause mor-
tality (HR 6.3 [95% CI 2.4–16.3], P 
0.001) in a Cox regression analysis. This
relationship persisted after adjusting for
age, sBP, and eGFR (3.6 [1.3–10.3], P 
0.014).
Similarly, 12 normoalbuminuric pa-
tients (3%) with GDF-15 levels below the
median versus 36 (8%) above the median
suffered a fatal or nonfatal cardiovascular
event during follow-up (HR 3.5 [95% CI
1.8–6.6],P0.001).Howeverwhenad-
justingforage,sBP,andeGFR,thiswasno
longer signiﬁcant (covariate-adjusted HR
1.8 [0.8–3.6], P  0.16).
The 451 patients with diabetic ne-
phropathy were divided into quartiles ac-
cording to GDF-15 levels (969; 970–
1,327; 1,328–2,172; and 2,173 ng/l,
respectively). Six patients (5%) with
GDF-15 levels in the ﬁrst quartile, 26
(23%) in the second, 47 (42%) in the
third, and 61 patients (54%) in the fourth
quartile died during follow-up (P 
0.001). A 15-fold increased risk of all-
cause mortality was found for high
(fourthquartile)versuslow(ﬁrstquartile)
GDF-15 levels (HR 15.84 [95% CI 6.84–
36.69], P  0.001). High GDF-15 levels
remained independently predictive of all-
cause mortality in the Cox regression
model (covariate-adjusted [sex, age,
smoking, BP, A1C, cholesterol, GFR, NT-
proBNP, antihypertensive treatment, and
previous cardiovascular events] 4.86
[1.37–17.30], P  0.015) (Table 2).
Regarding risk of fatal cardiovascular
events, four patients (4%) with GDF-15
levels in the ﬁrst quartile, 17 (15%) in the
second quartile, 29 (26%) in the third
quartile,and39(35%)inthefourthquar-
tile died of CVD during follow-up. Figure
1 shows the Kaplan–Meier curve for car-
diovascular mortality (P  0.001). High
(fourthquartile)versuslow(ﬁrstquartile)
GDF-15levelspredictedanincreasedrisk
of cardiovascular mortality (HR 14.64
[95%CI5.22–41.03],P0.001),which
persisted following covariate-adjustment
(5.59[1.23–25.43],P0.026)(Table2).
A similar independent predictive value of
GDF-15 was seen for nonfatal cardiovas-
cular events (n  99). High levels (fourth
quartile) versus low levels (ﬁrst quartile)
increased the risk of nonfatal cardiovas-
cular events when adjusting for con-
foundingfactors(3.55[1.08–11.64],P
0.036) (Table 2). GDF-15 concentrations
correlated with the cardiovascular risk
factorsNT-proBNP(r0.42,P0.001)
andmoreweaklywithCRP(r0.01,P
0.016).
TheoverallprognosticvalueofGDF-15
levels and other risk markers for all-cause
mortality were evaluated by ROC curves.
For GDF-15, the mean AUC was HR 0.79
(95% CI 0.74–0.84) as compared with
NT-proBNP(0.75[0.69–0.81])andGFR
(0.71 [0.64–0.77]). In comparison, the
AUCs for a combined risk score model—
including the previously mentioned co-
variateswithandwithoutGDF-15—were
0.84 (0.80–0.88) and 0.83 (0.78–0.87),
respectively. Regarding CVD mortality,
similar AUCs for the predictive value of
GDF-15 levels with and without covari-
ates were found (data not shown). Evalu-
ating GDF-15 as a continuous variable
introducedonlyminorchangesinthesta-
tisticaloutputs.Finally,whenperforming
the survival analyses for all patients
combined (n  891), adjusting for the
previously mentioned covariates and ne-
phropathy status, GDF-15 continued to
Table 1—Baseline clinical and laboratory characteristics of 891 type 1 diabetic patients
followed for 8.1 (0.0–12.9) years according to nephropathy status
Characteristic Nephropathy Normoalbuminuria P
n 451 440
Sex (men/women) 274/177 232/208 0.018
Age (years) 42.1  10.5 45.4  11.5 0.001
Duration of diabetes (years) 28.3  8.9 27.7  10.1 0.37
BMI (kg/m
2) 24.3  3.3 24.2  3.1 0.77
A1C (%) 9.4  1.5 8.4  1.1 0.001
Antihypertensive treatment (%)* 77.0 16.6 0.001
Systolic BP (mmHg) 144  22 134  19 0.001
Diastolic BP (mmHg) 82  12 76  10 0.001
Urinary albumin excretion rate (mg/24 h) 593 (3–14,545)† 9 (1–30) —
Serum creatinine (mol/l) 102 (52–706) 80 (53–134) 0.001
GFR (ml/min per 1.73 m
2) 76  33 — —
Serum cholesterol (mmol/l) 5.6  1.2 4.8  1.0 0.001
Smoking (%) 46.3 39.8 0.05
Retinopathy (0/SR/PR) 6/139/306 159/162/119 0.001
History of MI (%)‡ 4.2 2.1 0.05
History of stroke (%)‡ 6.9 1.6 0.001
NT-proBNP (ng/l) 89.1 (5–19,394) 42.8 (5–1,552) 0.001
GDF-15 (ng/l) 1,322 (443–17,735) 749 (158–13,933) 0.001
Data are n, means  SD, or median (range). *In 2002, the recommendations at the Steno Diabetes Center
were extended to include statins and low-dose aspirin for all patients with diabetic nephropathy. †Some
patientswithpreviouslypersistentmacroalbuminuriareceivingantihypertensivetreatmenthadvalues300
mg/24hatthetimeofinvestigation.‡PresenceofpreviousCVDisdeﬁnedaseitherMIorstroke.SR,simplex
retinopathy; PR, proliferative retinopathy.
Lajer and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 7, JULY 2010 1569be associated with all-cause and CVD
mortality(HR4.61[95%CI1.93–11.00],
P  0.001 and 5.04 [1.71–14.85], P 
0.003, respectively).
Progression of nephropathy
The mean (SD) rate of decline in GFR was
3.0 (2.9), 3.4 (3.6), 4.8 (4.0), and 6.3
(4.8) ml/min/1.73 m
2 /year (P  0.001),
respectively, when dividing the patients
according to quartiles of GDF-15. Fur-
thermore, when including the baseline
variables sex, age, A1C, systolic BP, GFR,
cholesterol,andantihypertensivetreatment
as covariates in the analysis, the GDF-15
levelsstillpredictedafasterrateofdeclinein
GFR during follow-up (P  0.001).
In addition, progression to chronic
dialysis or transplantation (ESRD) during
the follow-up period was seen in three
patientsintheﬁrstquartile(3%),fourpa-
tients in the second quartile (4%), 21 pa-
tients in the third quartile (19%), and 45
patients in the fourth quartile (47%) (P 
0.001). Cox regression analysis revealed
an increased risk (40 times) of ESRD in
patients with the highest GDF-15 levels
(fourth quartile) compared with the low-
estlevels(ﬁrstquartile)(HR39.9[95%CI
12.33–129.0], P  0.001). However this
association disappeared when adjusting
for confounding factors (2.08 [0.46–
9.40], P  0.34).
CONCLUSIONS — In the prospec-
tive observational analysis, including 8
years of follow-up, GDF-15 levels were
independently predictive of all-cause
mortality among the type 1 diabetic pa-
tientswithandwithoutdiabeticnephrop-
athy. In addition, among the 451 patients
withovertdiabeticnephropathy,elevated
levels of GDF-15 independently pre-
dicted CVD mortality and morbidity as
well as deterioration of renal function
(dGFR) after adjustment for conventional
CVD and renal risk factors including GFR
and NT-proBNP in multivariable models.
The elevated levels of GDF-15 may
reﬂect several underlying conditions
including acute/or chronic ischemia
associated with adverse cardiovascular
outcomesormaymerelyindicatereduced
renal excretion of GDF-15 due to renal
dysfunction. In particular, renal dysfunc-
tion appears to mediate part of the prog-
nostic impact of GDF-15 given the strong
inverserelationshipbetweenbaselinelev-
els of GDF-15 and eGFR in our study.
Thus,amongtheseveralconfoundingfac-
tors, impaired renal function may be par-
ticularly important since a reduced GFR
represents a cardiovascular risk factor by
itself and raises the possibility of residual
confounding by decreased renal clear-
ance. Therefore, we adjusted for several
conventionalCVDcovariatesinourstudy
includingGFRatbaseline.Theremaining
strong independent predictive value of
GDF-15 suggests mechanisms other than
renal dysfunction to account for the cor-
relation between CVD risk and GDF-15
levels. The possibility remains that ele-
vatedlevelsofGDF-15mayreﬂectacom-
pensatory production in individuals
suffering more severe CVD.
Circulating GDF-15 levels have pre-
Figure 1—Unadjusted Kaplan–Meier curves for CVD mortality among the 451 patients with
diabetic nephropathy according to quartiles of GDF-15 levels (969; 970–1,327; 1,328–2,172;
and 2,173 ng/l, respectively). First quartile (light gray line); second quartile (light gray dotted
line);thirdquartile(darkgraydottedline);andfourthquartile(blackline).Log-ranktestresulted
in P  0.001.
Table 2—HR of long-term cumulative mortality, cardiovascular mortality, and morbidity
after adjustment for confounding factors among the 451 patients with diabetic nephropathy
Parameter HR 95% CI P
All-cause mortality (n  140)
Second vs. ﬁrst quartile 1.90 0.60–6.03 0. 28
Third vs. ﬁrst quartile 3.75 1.22–11.57 0.022
Fourth vs. ﬁrst quartile 4.86 1.37–17.30 0.015
Cardiovascular mortality (n  89)
Second vs. ﬁrst quartile 1.76 0.44–6.97 0.42
Third vs. ﬁrst quartile 3.99 1.06–14.99 0.040
Fourth vs. ﬁrst quartile 5.59 1.23–25.43 0.026
Non-fatal cardiovascular event (n  99)
Second vs. ﬁrst quartile 2.36 0.91–6.13 0.079
Third vs. ﬁrst quartile 2.04 0.75–5.56 0.16
Fourth vs. ﬁrst quartile 3.55 1.08–11.64 0.036
All primary end points are adjusted for the following confounding factors: sex, age, smoking, A1C, systolic
BP, cholesterol, GFR, NT-proBNP, antihypertensive treatment, and a history of cardiovascular events at
baseline.
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risk factor for adverse cardiovascular
events including stroke and acute myo-
cardial infarction among women (12). At
the cellular level, GDF-15 mRNA and
propeptide expression is strongly in-
duced by both permanent and transient
ischemiainmiceandinpatientswhodied
after an MI (9). In addition, the gdf-15
gene–targeted mice have virtually normal
hearts under nonstressed conditions. In
contrast,theydevelopgreaterinfarctsizes
and greater extent of cardiomyocyte cell
death following the ischemia/reperfusion
injury that could be prevented by treat-
ment with recombinant GDF-15 (9).
Thus, GDF-15 may function as a neces-
sary protective factor to the heart in asso-
ciation with immediate and long-term
alterations in the hypertrophic response
antagonizingtheonsetorseverityofheart
failure, which is analogous to BNP.
Secretion of BNP and NT-proBNP is
induced from the heart following acute
and chronic stimulation associated
with cardiac injury and long-standing
disease that signals a protective and an-
ti-hypertrophicresponse(6,20).Circulat-
ing levels of NT-proBNP have previously
been shown to be associated with in-
creased mortality due to chronic heart
failure and acute coronary syndromes in
various disease states such as hyperten-
sion (21), ESRD (22), and of excess all-
cause and cardiovascular mortality in
both type 1 (19) and type 2 (23) diabetic
patients with diabetic nephropathy.
Thus,wealsoincludedNT-proBNPlevels
in the multivariate analysis. Still, elevated
GDF-15 levels remained independently
associated with CVD in an analogous
manner to circulating NT-proBNP levels
and as such may offer future therapeutic
targets for the treatment of hypertrophic
and dilated cardiomyopathy. However,
studies showing that GDF-15 levels are
modiﬁed by intervention are needed.
Recent data suggest that patients with
non-ST–elevation acute coronary syn-
drome with elevated GDF-15 levels ben-
eﬁt from early revascularization whereas
patients with lower levels of GDF-15 do
not (24). Thus, future studies should elu-
cidate whether GDF-15 could be infor-
mative as part of a multimarker strategy
identifying high-risk patients. The ROC
curve analysis further illustrated GDF-15
as a strong marker of mortality risk with
an AUC of 0.79 as compared with NT-
proBNP (HR 0.75 [95% CI 0.69–0.81])
and GFR (0.71 [0.64–0.77]). However,
in a combined risk score model including
the previously mentioned covariates,
GDF-15 only slightly improved the pre-
dictive accuracy of the model. This could
be due to the fact that the combined
model without GDF-15 has an AUC of
0.83 and, hence, the predictive accuracy
is difﬁcult to increase. Still, combining
markers of renal dysfunction, inﬂamma-
tion, and natriuretic peptides enhance
risk stratiﬁcation of type 1 diabetic pa-
tientswithandwithoutdiabeticnephrop-
athy and may provide additional insight
into pathophysiological mechanisms.
Although the cellular sources, up-
stream regulators, and functional effects
of GDF-15 in the cardiovascular system
remain to be fully elucidated, several de-
tails are emerging. Basal GDF-15 expres-
sion has so far only been detected in liver
and placenta tissue. However, studies of
cultured human kidney cells showed a
rapid rise in the secretion of mature
GDF-15 following injury, hypoxia, or cy-
tokine/growth factor stimulation due to a
dramatic induction of expression of
GDF-15 and not the release of stored
GDF-15 (8,11).
GDF-15 has been suggested to pro-
vide endogenous protection against car-
diomyocyte apoptosis possibly via a
PI3K-Akt–dependent pathway (9). In ad-
dition, GDF-15 treatment also transiently
activated Akt and ERK1/2 signaling, both
of which are thought to be cardioprotec-
tivepathways(10).Otherstudiesindicate
that bone marrow–derived GDF-15 pro-
tects against macrophage accumulation
within atherosclerotic lesions and pro-
motes lesion stabilization possibly due to
inhibitionofadhesionmolecules(25).Fi-
nally, the potential heterogeneity in the
mechanismofGDF-15activinindifferent
tissues or cell types may be attributable to
differential expression of the type I and
type II transforming growth factor- ac-
tivin receptors with afﬁnity for GDF-15.
Thus,GDF-15mightnotonlybeamarker
of ongoing tissue damage but actively in-
ﬂuence multiple downstream signaling
effectors as part of a cardioprotective
mechanism. However, a suggestive role
for GDF-15 therapy in improving treat-
ment and prevention of complications
among diabetic patients remains to be in-
vestigated further in both experimental
and clinical settings.
There are some limitations that
should be mentioned. Firstly, the end
point fatal CVD is based on death certiﬁ-
cates in contrast to nonfatal CVD events
that are based on information obtained
from the patients’ medical records. How-
ever, on a positive note, the number of
events may be underestimated and hence
the predictive value of GDF-15 could be
regarded as a conservative estimate.
Secondly, the stability of GDF-15 af-
ter 15	 years of storage is not known.
However, all samples of this study were
treated and stored at 80°C under the
same conditions. Furthermore, GDF-15
has been shown to be stable at room tem-
perature for 48 h and resistant to at
least four freeze-thaw cycles and, equally
important, the choice of anticoagulant
matrix had no inﬂuence on the measure-
ments (18).
In conclusion, higher levels of GDF-15
independently predicted all-cause and
cardiovascularmortalityandmorbidityin
patients with diabetic nephropathy be-
yond conventional cardiovascular risk
factors including NT-proBNP and GFR.
Furthermore, higher levels of GDF-15
were predictive of deterioration of kidney
function.Therefore,GDF-15maybecon-
sideredasanadditionalmarkerofinﬂam-
mation and atherosclerosis involved in
the pathogenesis of ischemic heart
disease.
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